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Brott TG, Halperin JL, Bacharach JM, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/
SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral
Artery Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force
on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses,
American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiol-
ogy, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovas-
cular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery,
Society for Vascular Medicine, and Society for Vascular Surgery Developed in Collaboration With the American
Academy of Neurology and Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2011;57:e16–94;
http://dx.doi.org/10.1016/j.jacc.2010.11.006.
In Section 5.1, the second item of the bulleted list beginning “Indications for carotid duplex sonography follow,” (p. e31),
“Follow-up of known stenosis (20%) in asymptomatic individuals,” “(20%)” was changed to “(50%).” It now reads,
“Follow-up of known stenosis (50%) in asymptomatic individuals.”
http://dx.doi.org/10.1016/j.jacc.2012.06.006
Frelinger III AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD.
A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole,
Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in
Healthy Volunteers. J Am Coll Cardiol 2012;59:1304–11.
There was an error in the number of subjects in Group 4 in Table 1. The correct table is printed below.
Summary of Demographic and Baseline Characteristics for All PPI GroupsTable 1 Su mary of Demographic and Baseline Characteristics for All PPI Groups
Characteristic
PPI Group 1:
Lansoprazole
(n  40)
PPI Group 2:
Dexlansoprazole
(n  40)
PPI Group 3:
Omeprazole
(n  40)
PPI Group 4:
Esomeprazole
(n  40)
Overall
(n  160)
Sex
Male 20 (50.0%) 20 (50.0%) 20 (50.0%) 20 (50.0%) 80 (50.0%)
Female 20 (50.0%) 20 (50.0%) 20 (50.0%) 20 (50.0%) 80 (50.0%)
Age (yrs) 32.8 6.48 (20–47) 35.7 7.92 (22–53) 34.0 7.40 (22–51) 33.3 7.10 (20–49) 33.9 7.26 (20–53)
Race
White 40 (100.0%) 39 (97.5%) 39 (97.5%) 39 (97.5%) 157 (98.1%)
American Indian or Alaska Native 0 0 1 (2.5%) 1 (2.5%) 2 (1.3%)
Native Hawaiian or Other Pacific
Islander
0 1 (2.5%) 0 0 1 (0.6%)
Ethnicity
Hispanic or Latino 40 (100.0%) 38 (95.0%) 38 (95.0%) 40 (100.0%) 156 (97.5%)
Not Hispanic or Latino 0 2 (5.0%) 2 (5.0%) 0 4 (2.5%)
Weight (kg) 70.1 10.29 70.8 9.95 68.6 7.44 71.6 10.83 70.3 9.69
Height (cm) 164.3 8.91 165.0 8.49 162.3 8.40 164.3 8.73 163.9 8.61
BMI (kg/m2) 25.9 2.26 26.0 2.41 26.1 2.16 26.4 2.50 26.1 2.32
Values are n (%) or mean  SD (range).
BMI  body mass index; PPI  proton pump inhibitor.
